Copy Number Variation (CNV) Analysis: Principles, Methods, and Applications

Copy number variation (CNV) analysis is a cornerstone of modern molecular genetics, enabling the detection of deletions and duplications of genomic DNA that underlie inherited diseases, cancer, and trait variation. This technical article provides a comprehensive overview of CNV analysis, covering core principles, sample requirements, testing items, detection methodologies, quality standards, and practical applications across clinical, research, and biotechnology fields.

Technical Overview

Copy number variations (CNVs) are segments of genomic DNA, typically defined as 1 kb or larger, that are present at a variable copy number compared to a reference genome. CNVs include deletions, duplications, insertions, and more complex rearrangements, and they collectively span a substantial fraction of the human genome. Because CNVs can disrupt genes, alter gene dosage, unmask recessive alleles, or create fusion products, they represent a major category of pathogenic variants in clinical genetics.

Copy number variation analysis refers to the laboratory and computational processes used to detect, quantify, and interpret these structural changes. Depending on the technology employed, CNV analysis can achieve resolution ranging from the whole-chromosome level down to single-exon events. Modern workflows combine molecular detection platforms with bioinformatic pipelines, curated databases, and clinical interpretation frameworks to deliver actionable results.

Accredited third-party laboratories performing CNV analysis typically operate under quality management systems conforming to ISO/IEC 17025 for testing laboratories or ISO 15189 for medical laboratories. These frameworks govern assay validation, analytical sensitivity, specificity, precision, and reporting, ensuring that results are technically defensible and clinically reliable.

Testing Samples

Human Peripheral Blood

Peripheral blood collected in EDTA anticoagulant tubes is the most common sample type for constitutional CNV analysis. A typical requirement is 2–5 mL of blood with a minimum genomic DNA yield of 200 ng to 1 µg, depending on the platform. Blood samples should be transported under controlled temperature conditions and processed within a validated stability window.

Saliva and Buccal Swabs

Non-invasive sampling via saliva collection kits or buccal swabs is suitable for patients where venipuncture is difficult, such as neonates or large family cohort studies. These samples require careful handling to minimize bacterial DNA contamination and ensure sufficient human DNA fraction.

Prenatal Samples

Amniotic fluid, chorionic villus samples (CVS), and cultured amniocytes are used for prenatal CNV detection following invasive sampling procedures. Maternal cell contamination testing is routinely performed alongside CNV analysis to confirm sample origin and detect potential mosaic results.

FFPE and Fresh-Frozen Tissue

Formalin-fixed paraffin-embedded (FFPE) tissue sections and fresh or frozen tumor specimens are used for somatic CNV profiling in oncology. DNA extracted from FFPE material is often fragmented, so methods tolerant of degraded DNA, such as low-pass whole-genome sequencing or targeted read-depth approaches, are preferred.

Cell-Free DNA and Plasma

Plasma-derived cell-free DNA (cfDNA) supports non-invasive CNV applications, including fetal aneuploidy screening and liquid biopsy tumor profiling. These workflows demand high-efficiency low-input DNA library preparation and strict control of fragment size distribution.

Research and Biotechnology Samples

Animal and plant tissues, cell lines, and genomic DNA from gene-edited or transgenic organisms are accepted for research-grade CNV applications such as transgene copy number determination, zygosity testing, and clonal characterization.

Testing Items

Common testing items offered within CNV analysis programs include:

• Whole-genome CNV screening for submicroscopic deletions and duplications
• Chromosomal aneuploidy detection (trisomy 21, 18, 13, and sex chromosome aneuploidies)
• Known microdeletion and microduplication syndrome evaluation
• Single-gene exon-level CNV detection, including events in genes such as DMD, PMP22, SMN1, SMN2, and CYP2D6
• Somatic copy number alterations in tumor genomes, including amplifications of ERBB2, EGFR, MYCN, and CCND1, and deletions such as CDKN2A loss
• Genome-wide loss of heterozygosity (LOH) and copy-neutral LOH assessment via SNP-informed platforms
• Mosaicism quantification for chromosomal or segmental imbalances
• Transgene insertion copy number and zygosity determination in genetically modified or gene-edited lines
• Vector copy number and genome integrity assessment in cell and gene therapy product characterization

Testing Methods

Array-Based Platforms

Array comparative genomic hybridization (aCGH) uses differentially labeled patient and reference DNA hybridized to oligonucleotide probes across the genome, detecting unbalanced copy number changes with typical resolution of 50–100 kb. SNP microarrays combine copy number probes with single nucleotide polymorphism probes, adding the ability to detect long contiguous stretches of homozygosity, consanguinity, and uniparental disomy.

Real-Time Quantitative PCR

qPCR-based dosage analysis compares amplification of a target locus against reference genes using relative quantification. It is a rapid, cost-effective method suited to targeted CNV interrogation of a limited number of genes or exons, with turnaround times of one to three days.

Multiplex Ligation-Dependent Probe Amplification (MLPA)

MLPA uses probe pairs that hybridize adjacently to target sequences and are ligated and PCR-amplified to allow multiplex copy number quantification of dozens of loci in a single reaction. It is a well-established method for exon-level CNV detection in disease genes with high deletion-duplication burdens.

Digital PCR

Droplet digital PCR and chip-based digital PCR partition reactions into thousands of individual compartments, enabling absolute copy number quantification without reference curves. Digital PCR delivers high precision for low-level mosaicism, transgene copy number confirmation, and therapy product lot release testing.

Next-Generation Sequencing Approaches

Low-pass whole-genome sequencing (LP-WGS) generates genome-wide read-depth profiles at approximately 0.1× to 0.5× coverage, providing resolution near 5 Mb and high sample throughput for aneuploidy and large CNV screening. Whole-exome sequencing and targeted panel sequencing support CNV calling through normalized read-depth algorithms, allowing simultaneous detection of sequence variants and exon-level CNVs. Whole-genome sequencing at higher coverage offers the most comprehensive resolution for both balanced and unbalanced structural variation.

Bioinformatic Analysis and Interpretation

Sequencing-based CNV pipelines incorporate read-depth normalization, GC-content bias correction, segmentation algorithms such as circular binary segmentation, and statistical calling models. Candidate CNVs are annotated against population databases, curated variant resources, and published literature, then classified according to internationally recognized variant interpretation guidelines. Findings are orthogonal-confirmed where appropriate using qPCR, digital PCR, MLPA, or FISH, and reported with coordinates, size, genes involved, zygosity, and classification.

Quality Assurance

Validated workflows include defined analytical performance characteristics, positive and negative controls in each run, participation in external quality assessment schemes, and reference-material traceability where available. Accredited third-party laboratories maintain documented procedures consistent with ISO/IEC 17025 or ISO 15189, and method validation reports are available to clients upon request.

Applications

Copy number variation analysis supports a wide range of clinical, research, and industrial use cases:

• Clinical genetics: first-tier evaluation of developmental delay, intellectual disability, autism spectrum disorder, and multiple congenital anomalies, where pathogenic CNVs are identified in a significant proportion of affected individuals.
• Prenatal and reproductive medicine: rapid aneuploidy detection, microdeletion screening, and preimplantation genetic testing for structural rearrangements (PGT-SR).
• Oncology: tumor profiling of amplifications and deletions that inform prognosis, therapy selection, and minimal residual disease monitoring.
• Pharmacogenomics: gene dosage assessment for loci where copy number directly affects drug metabolism and dosing decisions.
• Agricultural and animal breeding: CNV markers associated with production traits, disease resistance, and breed diversity studies.
• Biotechnology product development: characterization of transgenic lines, gene-edited clones, and cell banks; vector copy number and genome integrity testing for cell and gene therapy products under development.
• Academic research: genome-wide association studies, population genetics, and functional genomics investigations of structural variation.

FAQ

What is the difference between a CNV and a sequence variant?

A CNV is a structural change involving the loss or gain of a larger genomic segment, altering gene dosage, whereas sequence variants such as SNVs and small indels affect one or a few nucleotides. Comprehensive genetic testing often combines both variant classes to maximize diagnostic yield.

What resolution can CNV analysis achieve?

Resolution depends on the platform: karyotyping resolves multi-megabase events, SNP arrays and aCGH typically resolve 50–200 kb, targeted sequencing methods can detect single-exon events, and whole-genome sequencing can approach breakpoint-level resolution for some rearrangements.

Can CNV analysis detect mosaicism?

Yes. Array and sequencing platforms can detect mosaic CNVs typically down to approximately 20–30% mosaicism, while digital PCR may achieve sensitivity below 5% for defined, targeted loci. Reported mosaic levels should be interpreted with the analytical sensitivity of the method in mind.

How much DNA is required for testing?

Requirements vary by method: qPCR and MLPA generally require 50–250 ng, arrays typically require 500 ng to 1 µg, and sequencing workflows range from 10 ng for low-pass WGS to 200 ng or more for exome and genome sequencing. DNA integrity and purity thresholds are specified in individual assay instructions.

What is a typical turnaround time?

Targeted assays such as qPCR, digital PCR, and MLPA are usually completed within 5–10 working days. Array-based testing typically requires 10–15 working days, and sequencing-based analysis ranges from 10 to 25 working days depending on panel scope and data analysis complexity.

How are detected CNVs classified?

CNVs are classified into categories such as pathogenic, likely pathogenic, uncertain significance, likely benign, and benign, based on evidence from curated databases, peer-reviewed literature, inheritance patterns, and population frequency data, following internationally recognized interpretation frameworks.

Do all CNVs cause disease?

No. CNVs are a normal component of human genomic variation, and many are benign or of uncertain significance. Interpretation requires professional clinical context, and genetic counseling is recommended when results are applied to patient care.